Oct 21 (Reuters) - Laboratory operator Quest Diagnostics DGX.N raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests.
Shares of the New Jersey-based company were up 2.7% in premarket trading.
Quest expects 2025 adjusted profit between $9.76 and $9.84 per share versus its previous range of $9.63 to $9.83 per share.
It sees annual revenue at $10.96 billion to $11 billion, above its prior view of $10.80 billion to $10.92 billion.
While healthy demand for non-urgent surgeries, particularly among older Americans, has driven increased demand for diagnostic checkups, companies like Quest and Labcorp LH.N have also benefited from deals to manage hospital labs as they seek market share gains.
Quest's revenue for the third quarter rose 13.1% to $2.82 billion, beating analysts' average estimate of $2.74 billion, according to data compiled by LSEG.
The company said it expects new legislation, including the Trump administration's One Big Beautiful Bill Act, and the scheduled expiration of enhanced Affordable Care Act tax credits at the end of 2025, to not have a material impact on revenue in 2025 and 2026.
The changes could trim consolidated revenue by up to 50-60 basis points by 2028 compared with 2025, mainly due to lower Obamacare or ACA exchange insurance plan revenue.
The OBBBA imposes stricter eligibility verification and ends automatic re-enrollment for ACA customers, while the lapse of enhanced tax credits will raise premiums for millions of enrollees.
On an adjusted basis, Quest posted a profit of $2.60 per share for the quarter ended September 30, above analysts' average estimate of $2.50.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shailesh Kuber)
((Puyaan.Singh@thomsonreuters.com;))